We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Bruker Introduces Three Major High-Performance Mass Spectrometry Platforms and Applied Proteomics Solutions

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
At the 57th ASMS Conference on Mass Spectrometry and Allied Topics, Bruker Daltonics launches three completely new, major high-performance mass spectrometry platforms for life-science applications in proteomics, small molecule research and applied markets, as well as in clinical research and IVD applications.

With the introduction of three major new mass spec product lines, and significant advances in its applied proteomics solutions, Bruker Daltonics is embarking on a bold mission to set new performance and application standards in many areas of life-science mass spectrometry.

At ASMS 2009, Bruker launches three all-new, truly innovative major mass spectrometry platforms, each of which has been announced with a dedicated, detailed press release in recent weeks:

• ultrafleXtreme™ is the only fully 1,000 Hz MS and MS/MS enabled MALDI-TOF/TOF system, and incorporates proprietary new smartbeam™-II laser technology and a 4 GHz digitizer. Its proteomics performance is unmatched with broad-band mass resolving power up to 40,000 and 1 ppm mass accuracy.

A self-cleaning ion source, imaging software and laser focus diameters down to 10 µm make it ideal for MALDI imaging. Its flexibility allows LC-MALDI TOF/TOF proteomics, quantitative label-free proteomics, MALDI imaging, top-down proteomics, Edmass™ protein sequencing, intact protein analysis, polymer research and oligonucleotide analysis.

• amaZon™ is said to be the fastest ion trap mass spectrometer in the world with 52,000 u/second scan rate at 0.58 u mass resolution, and zero-delay polarity switching 20 Hz MS acquisition when coupled to UHPLC fast chromatography systems. Due to its dual ion funnel technology it offers an order of magnitude jump in sensitivity.

Second-Generation ETD and PTR options for proteomics offer ETD sensitivity due to its uncomplicated design. Ultimate ion trap mass resolving power up to 20,000 in full scan mode across the 50-3000 m/z range that is fast enough to be useable at LC speeds, make real-world LC top-down ETD experiments a reality. Its full-scan MS speed and MS/MS sensitivity allow it to obsolete many triple-quadrupole MRM methods for quantitation of large target analyte lists in applied markets from toxicology, food safety, doping and forensics.

• solariX™ offers a 10-fold improvement in F™S sensitivity, an 8-fold gain in broadband ultra-high resolution of >1,000,000 at 7 Tesla, and sub-ppm mass accuracy over a wide dynamic range. A complete engineering redesign makes this instrument robust, consistent and easy to use.

In addition to its new product launches, at ASMS 2009 Bruker Daltonics is also further advancing various applied proteomics solutions, leveraging its leadership in MALDI mass spectrometry:

• The top-down Edmass™ protein sequencing solution offers a faster and convenient next-generation protein sequencing solution for all biologists and life-science researchers.

Bruker's well established MALDI Biotyper solution for microbial identification in clinical microbiology has recently obtained an IVD-CE mark with a Declaration of Conformity in accordance with the European Union in Vitro Diagnostic Directive 98/79/EC.

The MALDI Biotyper offers fast time to result, and higher specificity. It has the potential to become the new ‘gold standard’ in clinical microorganism identification.

Carl Zeiss’ MIRAX Virtual Slide Scanner and Bruker's MALDI Molecular Imager™ now enable non-targeted molecular histology with high spatial resolution in an integrated solution for biological tissue research and clinical pathology research.